C-reactive protein and monitoring the activity of Crohn's disease

Advances in Therapy

Volumn 23, Issue 4, 2006, Pages 655-662

  Filik, Levent ^a   Dagli, Ulku ^b   Ulker, Aysel ^b  

^a Ankara Teaching and Research Hospital   (Turkey)

^b TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

C reactive protein; Colonoscopy; Crohn's disease; Crohn's Disease Activity Index

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CIPROFLOXACIN; GLUCOCORTICOID; MESALAZINE; METHOTREXATE; METRONIDAZOLE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; COLITIS; COLONOSCOPY; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; ILEITIS; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 33750987649     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850054     Document Type: Article

References (25)

1. Vermeire S, Assche GV, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflam Bowel Dis. 2004;10:661-665.
2. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Fera A. Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther. 2003;17(suppl 2):11-17.
3. Yoshida EM. The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol. 1999;13:65-73.
4. Tromm A, Tromm CD, Huppe D, Schwegler U, Krieg M, May B. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol 1992;27:774-778.
5. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol. 2002;14:409-412.
6. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister ER, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflam Bowel Dis. 2005;11:707-712.
7. Hodgson HJF, Bhatti M. Assessment of disease activity in ulcerative colitis and Crohn's disease. Inflam Bowel Dis. 1995;1:117-134.
8. Arnott IDR, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther. 2002;16:857-867.
9. Rosalki SB. C-reactive protein. Int J Clin Pract. 2001;55:269-270.
10. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NHH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359-367.
11. Vatay A, Bene L, Kovacs A, et al. Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease. Immunogenetics. 2003;55:247-252.
12. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index: National Cooperative Crohn's disease study. Gastroenterology. 1976;70:439-444.
13. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7:460-465.
14. Arnott ID, Drummond HE, Ghosh S. Frequency of continuing mucosal inflammation in clinically inactive Crohn's disease. Scott Med J. 2001;46:136-139.
15. Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffiths AM. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology. 1999;116:527-531.
16. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonie or ileocolonic Crohn's disease: a prospective multicentre study of 121 cases. Gut. 1994;35:231-235.
17. Boirivant M, Leoni M, Tariciottti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. J Clin Gastroenterol. 1988;10:401-405.
18. Pinchbeck BR, Imes S, Dinwoodie A, Thomson ABR. Discriminant function analysis to calculate a Crohn's activity group scale to predict future inactive or active disease. J Clin Gastroenterol. 1988;10:498-504.
19. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut. 1989;30:983-989.
20. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology. 1982;83:550-562.
21. Cooke WT, Prior P. Determining disease activity in inflammatory bowel disease. J Clin Gastroenterol. 1984;6:17-25.
22. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
23. Ganesan S, Travis SP, Ahmad T, Jazrawi R. Role of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs. 2002;3:1297-1300.
24. Ghosh S. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: the role of natalizumab. Expert Opin Biol Ther. 2003;3:995-1000.
25. Kumar S, Boehm J, Lee JC. MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2:717-726.